Sunesis Pharmaceuticals (SNSS) Given News Impact Score of 0.20
Press coverage about Sunesis Pharmaceuticals (NASDAQ:SNSS) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sunesis Pharmaceuticals earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.4921263567427 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s rankings:
- Sunesis Pharmaceuticals, Inc. (SNSS) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Sunesis Pharmaceuticals, Inc. (SNSS) Forms $3.24 Double Bottom … – Hill Country Times (hillcountrytimes.com)
- Sunesis Pharmaceuticals (SNSS) Now Covered by Oppenheimer (americanbankingnews.com)
- Pre-Open Movers 12/11: (BLUE) (BPMC) (SNSS) Higher; (SYRS) (ONCE) (GBT) Lower (more…) (streetinsider.com)
Shares of Sunesis Pharmaceuticals (SNSS) opened at $3.30 on Wednesday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34. Sunesis Pharmaceuticals has a 52-week low of $1.82 and a 52-week high of $4.45.
Several brokerages have commented on SNSS. Cantor Fitzgerald set a $3.00 target price on shares of Sunesis Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, December 5th. Oppenheimer began coverage on shares of Sunesis Pharmaceuticals in a report on Thursday, December 14th. They issued a “buy” rating and a $7.00 target price for the company. Zacks Investment Research upgraded shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a report on Thursday, August 24th. Wells Fargo & Company upgraded shares of Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their target price for the stock from $2.86 to $2.48 in a report on Monday, December 11th. Finally, Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $3.75.
In other Sunesis Pharmaceuticals news, Director Dayton Misfeldt acquired 400,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The shares were purchased at an average price of $2.00 per share, with a total value of $800,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Mpm Oncology Impact Management acquired 25,300 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were acquired at an average cost of $2.59 per share, for a total transaction of $65,527.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 506,800 shares of company stock worth $1,091,282. Insiders own 10.21% of the company’s stock.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.